Is there discrimination in access to therapy for HCV patients?
Language English Country Netherlands Media print-electronic
Document type Editorial, Comment
Persistent link
https://www.medvik.cz/link/pmid18678432
PubMed
18678432
DOI
10.1016/j.jhep.2008.07.003
PII: S0168-8278(08)00432-7
Knihovny.cz E-resources
- MeSH
- Antiviral Agents economics therapeutic use MeSH
- Healthcare Disparities economics MeSH
- Health Services Accessibility MeSH
- European Union MeSH
- Hepacivirus * MeSH
- Hepatitis C drug therapy economics MeSH
- Interferon alpha-2 MeSH
- Interferon-alpha economics therapeutic use MeSH
- Humans MeSH
- Polyethylene Glycols economics therapeutic use MeSH
- Prejudice * MeSH
- Recombinant Proteins MeSH
- Ribavirin economics therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Comment MeSH
- Editorial MeSH
- Geographicals
- Czech Republic MeSH
- Canada MeSH
- Names of Substances
- Antiviral Agents MeSH
- Interferon alpha-2 MeSH
- Interferon-alpha MeSH
- peginterferon alfa-2a MeSH Browser
- peginterferon alfa-2b MeSH Browser
- Polyethylene Glycols MeSH
- Recombinant Proteins MeSH
- Ribavirin MeSH
Comment On
References provided by Crossref.org
